Fosun Pharma’s Henlius Strikes Deal with Sandoz for Global Rights to HLX13 Biosimilar
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its subsidiary...
Cancer
AstraZeneca’s Q1 2025 Results: 10% Revenue Growth, Oncology Segment Shines
UK-based AstraZeneca (NASDAQ: AZN) released its Q1 2025 financial results, showing a 10% year-on-year (YOY)...
Pfizer’s Q1 2025 Results: Revenues Down 6% YOY Amid Paxlovid, IRA Impact
US-based Pfizer Inc. (NYSE: PFE) released its Q1 2025 financial results, showing a -6% year-on-year...
Innovent Biologics Expands Clinical Partnership with ImmVirX to Include Hepatocellular Carcinoma
China-based Innovent Biologics Inc. (HKG: 1801) announced the expansion of its existing clinical cooperation and...
Boehringer Ingelheim’s Zongertinib Shows Promising Results in HER2-Mutant NSCLC Trial
German pharmaceutical giant Boehringer Ingelheim has released the latest results from the Beamion LUNG-1 trial,...
Johnson & Johnson’s TAR-200 Shows Promising Results in Phase IIb SunRISe-1 Study for Bladder Cancer
US giant Johnson & Johnson (J&J; NYSE: JNJ) has released the first results from Cohort...
Regeneron’s Lynozyfic Gains EC Conditional Approval for Relapsed Multiple Myeloma
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that it has received conditional marketing authorization from the...
BeiGene’s Sonrotoclax NDA Accepted by NMPA for CLL/SLL Treatment
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change...
Henlius Biotech’s HLX22 Receives Clinical Trial Approval in Germany for HER2-Positive Cancers
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced that it has received clinical trial approval...
Hengrui Pharmaceuticals Gains NMPA Clinical Clearance for Camrelizumab in Acral Melanoma
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clinical clearance...
Shouyao Holdings Gets Ethics Approval for SY-5933 Phase Ib/II Study in KRAS G12C Mutated Tumors
Beijing-based Shouyao Holdings (Beijing) Co., Ltd (SHA: 688197) announced that it has received ethical approval...
Biokin’s BL-B01D1 Secures NMPA Green-light for Two Phase II Clinical Trials in Gynecological Cancers
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has received approval from the National Medical...
Pfizer’s Inlyta Receives NMPA Approval for First-line Renal Cell Carcinoma Combination Therapy
US giant Pfizer Inc. (NYSE: PFE) announced last week that it has received marketing approval...
Anglikang Pharmaceutical Receives NMPA Clinical Clearance for ALK-N001 in Advanced Solid Tumors
China-based Zhejiang Anglikang Pharmaceutical Co., Ltd (SHE: 002940) announced that it has received clinical clearance...
Grand Pharma’s AcornMed utLIFE-UC Urothelial Carcinoma Assay First Prescription Administered in China
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced the first prescription of AcornMed utLIFE-UC,...
CSPC Pharmaceutical Gains FDA IND Clearance for JMT203 in Cancer Cachexia
China-based CSPC Pharmaceutical Group Limited (HKG: 1093) has obtained Investigational New Drug (IND) clearance from...
Biokin Receives NMPA Approval for CD33 ADC in AML Trial
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has received approval...
Novocure Wins CE Mark for Optune Lua in Metastatic NSCLC Treatment
Switzerland-based Novocure (NASDAQ: NVCR), the developer of Tumor Treating Fields (TTFields) for cancer therapy, has...
Akeso’s Ivonescimab Shows Strong Results in Phase III Trial for Sq-NSCLC
China-based Akeso, Inc. (HKG: 9926) announced strongly positive results from the regulatory Phase III AK112-306/HARMONi-6...
BMS Secures NMPA Approval for Opdivo in Resectable NSCLC Neoadjuvant Therapy
Bristol-Myers Squibb (BMS, NYSE: BMY) has announced additional indication approval from China’s National Medical Products...